TLR9 Blocking Peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9EQU3 |
---|---|
Other Accession | NP_112455 |
Gene ID | 81897 |
Calculated MW | 116412 Da |
Gene ID | 81897 |
---|---|
Application & Usage | The peptide is used for blocking the antibody activity of TLR9. It usually blocks the antibody activity completely in Western blot analysis by incubating the peptide with equal volume of antibody for 30-60 minutes at 37°C. |
Other Names | Toll-like receptor 9, CD289, Tlr9 |
Target/Specificity | TLR9 |
Formulation | 50 µg (0.5 mg/ml) in phosphate buffered saline (PBS), pH 7.2, containing 50% glycerol, 1% BSA and 0.02% thimerosal. |
Reconstitution & Storage | -20 °C |
Background Descriptions | |
Precautions | TLR9 Blocking Peptide is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | Tlr9 |
---|---|
Function | Key component of innate and adaptive immunity. TLRs (Toll- like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR9 is a nucleotide-sensing TLR which is activated by unmethylated cytidine- phosphate-guanosine (CpG) dinucleotides. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed:18931679, PubMed:21402738, PubMed:14993594, PubMed:17474149, PubMed:25686612, PubMed:18820679). Plays a role in defense against systemic mouse cytomegalovirus infection (PubMed:14993594). Controls lymphocyte response to Helicobacter infection (PubMed:17474149). Upon CpG stimulation, induces B-cell proliferation, activation, survival and antibody production (By similarity). |
Cellular Location | Endoplasmic reticulum membrane; Single-pass type I membrane protein. Endosome. Lysosome. Cytoplasmic vesicle, phagosome. Note=Relocalizes from endoplasmic reticulum to endosome and lysosome upon stimulation with agonist (PubMed:18305481). Exit from the ER requires UNC93B1 (PubMed:18820679) Endolysosomal localization is required for proteolytic cleavage and subsequent activation (PubMed:18931679, PubMed:18820679). Intracellular localization of the active receptor may prevent from responding to self nucleic acid (PubMed:18820679). |
Tissue Location | Expressed in the basolateral region of gastric epithelial cells with high levels detected in antrum and body mucosa (at protein level). Detected in spleen and stomach at higher levels in C57BL/6 mice than BALB/C. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.